Introduction
Invasive candidiasis (IC) is a major threat to the health of patients in hospitals as well as in the community and its consequent mortality is costly. 1 -4 Although Candida albicans remains the most common aetiological agent overall, non-albicans Candida species are increasingly encountered, 5 -7 and in some countries these species account for more episodes of IC, including candidaemia, than C. albicans. 8 -12 The relative frequency of Candida species other than C. albicans also varies with region. For example, Candida glabrata is the second most common species after C. albicans in North America. 13 In Europe, Australia, Latin America and Asia, however, Candida parapsilosis or Candida tropicalis is relatively more common. 8, 9, 14 In India, C. tropicalis causes even more cases of candidaemia than C. albicans. 15, 16 In addition, uncommon species such as Candida guilliermondii and Candida rugosa, and novel species, e.g. Candida quercitrusa, are emerging. 17 -19 Given that many non-albicans Candida spp. are resistant or less susceptible to antifungal agents, 17 -19 there is a continuing need to determine the antifungal susceptibility patterns of these organisms. Further, the data from one region may not be transferable to another. In China, the epidemiology of IC and associated antifungal susceptibility patterns of Candida spp. remains incompletely defined. 9, 20 To address these deficiencies, a prospective nationwide study, the China Hospital Invasive Fungal Surveillance Net (CHIF-NET), was initiated in 2009 to monitor trends in the epidemiology of yeast infections over a 3 year period and to provide up-to-date susceptibility data on antifungal drugs. 9 The CHIF-NET survey reported the susceptibilities of yeasts collected during the first year of the study (n¼814 isolates) to fluconazole and voriconazole using the CLSI M44-A2 disc diffusion method. 9, 21 However, there were no data on susceptibilities to the echinocandin drugs.
Here, we extend the evaluation of antifungal susceptibilities of C. parapsilosis species complex, C. tropicalis, C. glabrata species complex and C. krusei collected during the 3 years of the CHIF-NET study to nine antifungal agents. We employed the Sensititre YeastOne TM YO10 (Sensititre; Thermo Scientific, Cleveland, Ohio, USA) system, which is based on CLSI methodology, 22 and used current speciesspecific clinical breakpoint (CBPs) or epidemiological cut-off values (ECVs) for Candida spp. to assign susceptibility or resistance. 23, 24 For all isolates, susceptibility to fluconazole and voriconazole was also studied by CLSI M44-A2 disc diffusion testing 9, 21 and categorical agreements between the results obtained using the two methods were compared.
Materials and methods

Study design and collection of isolates
The CHIF-NET study was a prospective, laboratory-based, multicentre study of invasive yeast infections beginning in August 2009 as previously described. 9 During the second and third years of the study (ending in July 2012), the number of surveillance sites expanded from 12 to 22 tertiary hospitals. A total of 11 hospitals (eight major cities) participated in the study for the 3 years (see the Acknowledgements section for study sites and hospitals). To ensure the coherence and consistency of epidemiology and antifungal susceptibility data over the 3 years, only isolates from the above 11 hospitals were included in the present study.
The CHIF-NET study inclusion criteria were as previously described. 9 All isolates were forwarded to the Department of Clinical Laboratory, Peking Union Medical College Hospital for species confirmation and antifungal susceptibility testing. The study was approved by the Human Research Ethics Committee of Peking Union Medical College Hospital (S-263).
Species identification
A total of 1072 isolates were studied comprising 392 (36.6%) C. parapsilosis species complex (325 C. parapsilosis sensu stricto, 43 C. metapsilosis, 14 C. orthopsilosis and 10 Lodderomyces elongisporus), 379 (35.4%) C. tropicalis, 261 (24.3%) C. glabrata species complex (258 C. glabrata sensu stricto and 3 C. nivariensis) and 40 (3.7%) C. krusei strains (Table 1) .
Isolates from Year 1 of the study were identified by DNA sequencing of the fungal internal transcribed spacer (ITS) regions as previously reported, 9 while isolates from Years 2 and 3 were identified by MALDI-TOF MS (Vitek MS, bioMérieux, Marcy-l'Étoile, France) supplemented with ITS sequencing according to the algorithm of Zhang et al. 25 
Antifungal susceptibility testing
The in vitro susceptibility to nine antifungal drugs-fluconazole, voriconazole, itraconazole, posaconazole, caspofungin, micafungin, anidulafungin, amphotericin B and 5-flucytosine-was determined using Sensititre YeastOne TM YO10 methodology (Thermo Scientific) following the manufacturer's instructions. In addition, susceptibility to fluconazole and voriconazole was determined for all 1072 isolates using the CLSI M44-A2 disc diffusion protocol. 9, 21 For each run, the quality control strains were C. parapsilosis ATCC 22019 and C. krusei ATCC 6258.
MIC values determined by the Sensititre YeastOne TM YO10 method (Thermo Scientific) were interpreted according to current CLSI speciesspecific CBPs (Table S1 , available as Supplementary data at JAC Online). 23 Where there were no CBPs defined, species-specific ECVs were used to define isolates as WT or non-WT. 24 Cross-resistance was defined as resistance to, or of the non-WT phenotype to, ≥2 antifungals of the same drug class. 26 For fluconazole and voriconazole, categorical agreements between the CLSI M44-A2 disc diffusion and Sensititre YeastOne TM YO10 (Thermo Scientific) results were calculated, with results obtained by the latter as the reference. Major errors were considered to be present when there was a classification of 'resistant' by the disc diffusion test and 'susceptible' by the Sensititre YeastOne TM . Very major errors were a classification of susceptible by the disc diffusion method and resistant by Sensititre YeastOne TM . Minor errors occurred when the result of one of the tests was susceptible or resistant, and that of the other test was susceptibledose-dependent (S-DD) or intermediate. 27 
Statistical analysis
All statistical analyses were performed using IBM SPSS software (version 22.0; IBM SPSS Inc., New York, USA). Categorical variables were compared using the x 2 or Fisher's exact test, and continuous variables by the MannWhitney U test. A P value of 0.05 was considered significant.
Results
Species distribution of common non-albicans Candida species
Of 1072 Candida isolates, members of the C. parapsilosis species complex were the most common (392 isolates; 36.6%) followed by C. tropicalis (35.4%) and C. glabrata species complex (24.3%) ( Table 1 ). C. krusei was uncommon (3.7%). Among the C. parapsilosis species complex, 17.1% of strains were those other than C. parapsilosis sensu stricto, while 98.9% of C. glabrata species complex isolates were C. glabrata sensu stricto. 
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In vitro susceptibility to azoles
In general, C. parapsilosis species complex was susceptible to all four azoles tested. Overall, susceptibility to fluconazole and voriconazole was observed for 97.7% (383/392) and 99.2% (389/392) for the species complex, respectively. All isolates were of the WT phenotype to itraconazole and posaconazole ( Table 1) . The rates of susceptibility to fluconazole and voriconazole were 97.5% (317/325 isolates) and 99.4% (323/325), respectively, for C. parapsilosis sensu stricto, while 97.7% (42/43) of the strains of C. metapsilosis and all of the C. orthopsilosis (14/14) and L. elongisporus (10/10) isolates were susceptible to these azoles. C. tropicalis isolates were less susceptible to the azoles [11.6% of isolates (44/379) and 9.5% (36/379) tested non-susceptible to fluconazole and voriconazole, respectively] ( Table 1 ). In addition, 31.7% (120/379) of the C. tropicalis isolates were non-WT to posaconazole, and 1.3% (5/379) of the isolates were non-WT to itraconazole. Geometric mean (GM) MIC values for the azoles were 2-to 4-fold higher against C. tropicalis than against C. parapsilosis species complex (P, 0.01) ( Table 1) . Twenty-seven (7.1%) C. tropicalis isolates were cross-resistant to azoles, including five (1.3%) that were resistant to, or were of the non-WT phenotype to, all four azoles (Table 2) .
Approximately 85.7% (221/258) C. glabrata sensu stricto isolates were S-DD (MICs ≤ 32 mg/L) to fluconazole and 14.3% (37/258) were resistant (MICs ≥64 mg/L). The non-WT rates of C. glabrata sensu stricto for voriconazole, itraconazole and posaconazole ranged between 9.3% and 12.0%. All three C. nivariensis isolates were S-DD to fluconazole and of the WT phenotype to voriconazole, itraconazole or posaconazole. The GM MIC values of voriconazole, itraconazole and posaconazole against C. glabrata species complex isolates were 1-to 3-fold higher than those against C. tropicalis (P, 0.01) and 4-to 6-fold higher than those against C. parapsilosis species complex (P, 0.01) ( Table 1) . Thirty (11.6%) C. glabrata sensu stricto isolates were cross-resistant to fluconazole and voriconazole, and 9.3% were resistant/non-WT to all four azoles (Table 2) .
Although resistant to fluconazole, all C. krusei were susceptible to voriconazole and were of the WT phenotype to itraconazole and posaconazole (Table 1) .
In vitro susceptibilities to the echinocandins
The susceptibility rates to all three echinocandins tested were similar for all the non-albicans Candida species studied. Caspofungin, micafungin and anidulafungin exhibited .99% susceptibility rates against all isolates with the exception of caspofungin against C. krusei [95% (38/40) of isolates were susceptible] (Table 1) and anidulafungin against C. glabrata sensu stricto [97.7% (252/258) susceptible]. Echinocandin GM MIC values against C. parapsilosis species complex were 2-to 6-fold higher than those against the other three non-albicans Candida species (P, 0.01) except for caspofungin against C. krusei (P ¼ 0.13) ( Table 1 ). The GM MIC values for L. elongisporus were 3-to 5-fold lower than those for other species within the C. parapsilosis species complex (P,0.01) ( Table 1 ).
In vitro susceptibilities to amphotericin B and 5-flucytosine
All isolates studied showed a WT phenotype to amphotericin B. The MIC 50 and MIC 90 values of amphotericin B for all four species/species complexes were either 0.5 or 1 mg/L (Table 1 ) and all isolates were inhibited at drug concentrations of ≤1 mg/L except for one isolate each of C. parapsilosis sensu stricto and C. krusei (MIC 2 mg/L).
Only 0.8% (3/392) of C. parapsilosis species complex and 1.1% (4/379) of C. tropicalis isolates were non-WT to 5-flucytosine. The GM MIC values of 5-flucytosine against C. parapsilosis species complex, C. tropicalis and C. glabrata species complex ranged from 0.04 to 0.12 mg/L. The MICs of all the C. krusei isolates were 16 mg/L (Table 1 ).
Three year trends of antifungal susceptibilities
The susceptibility rates of C. parapsilosis species complex isolates remained stable (97.4% -100%) for all the agents tested ( Figure 1 ). For C. tropicalis, the susceptibility rate to fluconazole decreased by over 4% to 85.1% in the third year of the study but this was not significant (P ¼ 0.29); similarly, the proportion of posaconazole WT strains dropped from 73.8% to 64.2% (P ¼ 0.11) (Figure 1 ). There were no significant trends in susceptibility to voriconazole, itraconazole and posaconazole among C. glabrata species complex strains over the 3 years ( Figure 1 ).
Specimen source and antifungal susceptibilities
Data on the distribution of isolates by specimen source, and the proportions of isolate that exhibited fluconazole resistance, are summarized in Table 3 . Isolates recovered from blood cultures comprised 25% -58.2% of the strains (depending on the species) and those from ascitic fluid accounted for 15.1% -26.4% (Table 3 ). All six fluconazole-resistant C. parapsilosis species complex isolates came from blood culture. In comparison, C. tropicalis isolates from tissue, central venous catheter (CVC), bronchoalveolar lavage (BAL) fluid and pus had rates of resistance to fluconazole that were higher (22.2%, 16.7%, 14.3% and 11.8%, respectively) than the mean rate (8.2%); C. glabrata species complex isolates from CVC and BAL fluid had higher fluconazole Xiao et al.
resistant rates (both 20%) than average (14.2%) ( Table 3 ; P ¼ not significant).
Categorical agreement between Sensititre YeastOne TM YO10 and disc diffusion methods
Overall, the Sensititre and disc diffusion methods exhibited good concordance in susceptibility testing results for fluconazole and voriconazole (categorical agreement .95%). Very major error and major errors occurred for 1.1% and 0.2% of isolates, respectively, in testing fluconazole susceptibilities, and 0.9% and 0.3% of isolates, respectively, in testing voriconazole susceptibilities. In addition, 3.3% and 3.2% minor errors occurred in testing fluconazole and voriconazole, respectively ( Table 4 ). The occurrence of very major errors was higher in C. tropicalis against fluconazole and C. glabrata species complex against voriconazole, although it did not exceed 2.7%. However, a major error rate of 7.5% (3/40 isolates) was found in testing voriconazole activity against C. krusei (Table 4) .
Discussion
Reliable, contemporary epidemiological data on species distribution and susceptibility are essential for informing early, targeted antifungal therapy in patients with IC and candidaemia, particularly for clinicians working in hospitals where antifungal susceptibility tests are not routinely carried out. Given that such epidemiological data for invasive yeast infections in China have been largely restricted either to studies in single centres or to a limited number of yeast species, 28 this large multicentre study provides clinically useful data on the susceptibilities to nine antifungal agents to treat common non-albicans Candida species across China.
A noteworthy finding of the present study is that the most common non-albicans Candida species encountered in Chinese hospitals was C. parapsilosis species complex (36.6%), followed closely by C. tropicalis (35.4%). Conversely, C. glabrata accounted for only 24.3% of isolates and C. krusei was uncommon. The results were in contrast to findings in the USA, where C. glabrata Susceptibility of common non-albicans Candida species in China is the most common non-albicans Candida species (.20% in candidaemia), 13, 29 as well as in India, where C. tropicalis is most common ( 40% of all cases of candidaemia). 15, 16 In addition, the prevalence of species other than C. parapsilosis sensu stricto among the C. parapsilosis species complex (e.g. C. metapsilosis, C. orthopsilosis and L. elongisporus) in this study (17.1%) was higher than that observed in the global ARTEMIS study and in other European and Latin American studies (prevalence ,10%). 5,30 -33 These findings emphasize the need to perform locally relevant epidemiological studies.
In vitro susceptibility results showed that members of the C. parapsilosis species complex were predominantly (≥97.5%) susceptible (or were WT) to all nine antifungals tested, with only a small proportion (≤1.5%) of C. parapsilosis sensu stricto isolates being resistant to fluconazole and voriconazole. The results are in general similar to those obtained from a global surveillance of the antifungal susceptibility of Candida species. 7, 29 Of note, although fluconazole-resistant C. parapsilosis species complex isolates were rare, all six were recovered from blood culture samples. Despite relatively higher echinocandin MICs, C. parapsilosis infections may be treated with the echinocandins with good outcomes. Our data indicate that these observations can be extended to IC caused by L. elongisporus as GM MICs of echinocandins for L. elongisporus were 3-to 5-fold lower than for other members of this species complex (P,0.01).
For C. glabrata species complex, we observed that 9.3% of C. glabrata sensu stricto isolates were resistant/non-WT to all four azoles tested. We also found that C. glabrata species complex isolates were largely (99.2%, 100% and 97.7%, respectively) susceptible to caspofungin, micafungin and anidulafungin. These results are comparable to those from the ARTEMIS and SENTRY studies.
7,29 Importantly, we did not observe co-resistance to azoles and the echinocandins among C. glabrata. This contrasts with recent US studies where .11% of fluconazole-resistant C. glabrata isolates were co-resistant to one or more echinocandins. 34, 35 Since we encountered only three C. nivariensis isolates, we were unable to determine varying drug susceptibilities between individual members of the C. glabrata species complex. C. nivariensis has previously been reported to be more resistant to azoles and flucytosine than C. glabrata sensu stricto. 36 Interestingly, 7.1% of C. tropicalis isolates were resistant to two or more azole agents. By applying the new CLSI CBPs, 23 the overall fluconazole and voriconazole susceptibilities against C. tropicalis isolates dropped by 4.7% and 5.3%, respectively (Table S2) . Although the azole non-susceptible isolates came from all 11 Xiao et al.
hospitals, clustered cases were noted in Hospital H1 in North-East China (see the Acknowledgements section; data not shown). The increased resistance of C. tropicalis to fluconazole and outbreaks of infection caused by fluconazole-resistant C. tropicalis have previously been recognized in Taiwan. 37, 38 Molecular typing is in progress to determine the genetic relatedness of the isolates in the present study.
Importantly, all the species studied here were susceptible to amphotericin B and 5-flucytosine, and although these two agents are not first-line antifungals in the treatment of IC and candidaemia in most clinical contexts, 39 they may have a role where the azoles or echinocandins cannot be used, or in salvage therapy.
As previously noted, the results obtained by Sensititre YeastOne TM and CLSI M44 disc diffusion were comparable. 40 -43 The overall category agreements between the two methods was .95% for both fluconazole and voriconazole, while very major and major errors only occurred in ,1.5% of cases. We noted that some previous studies had set up ECVs against common non-albicans Candida species based on Sensititre YeastOne TM methods, and the ECVs were within one dilution of those determined by the CLSI broth microdilution methods. 44, 45 Because ECVs based on Sensititre YeastOne TM methods had not been widely validated, we applied CLSI CBPs where applicable. 46 In conclusion, the study has provided useful data on the antifungal susceptibility of common non-albicans Candida species isolates from patients with invasive infections in China. C. parapsilosis species complex, the most common non-albicans Candida species, was susceptible to the azoles and echinocandins. In contrast, reduced susceptibility was observed among, e.g. C. tropicalis for the azoles. Studies to correlate in vitro resistance with clinical outcomes should be a priority.
